Aging dysregulates D- and E-series resolvins to modulate cardiosplenic and cardiorenal network following myocardial infarction

Aging

Volumn 8, Issue 11, 2016, Pages 2611-2634

  Halade, Ganesh V ^a   Kain, Vasundhara ^a   Black, Laurence M ^a   Prabhu, Sumanth D ^a   Ingle, Kevin A ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

Aging; Lipid mediators; Lipoxygenase; Macrophages; Myocardial infarction; Non resolving inflammation

Indexed keywords

DOCOSAHEXAENOIC ACID; ICOSAPENTAENOIC ACID; INTERLEUKIN 1BETA; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; TUMOR NECROSIS FACTOR;

AGING; ANIMAL; HEART INFARCTION; MALE; METABOLISM; MOUSE;

AGING; ANIMALS; DOCOSAHEXAENOIC ACIDS; EICOSAPENTAENOIC ACID; INTERLEUKIN-1BETA; LIPOCALIN-2; MALE; MICE; MYOCARDIAL INFARCTION; TUMOR NECROSIS FACTOR-ALPHA;

EID: 85001932751     PISSN: 19454589     EISSN: None     Source Type: Journal    
DOI: 10.18632/aging.101077     Document Type: Article

References (50)

1. Roger VL, Go AS, Lloyd-Jones DM, Benjamin EJ, Berry JD, Borden WB, Bravata DM, Dai S, Ford ES, Fox CS, Fullerton HJ, Gillespie C, Hailpern SM, et al, and American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics-2012 update: a report from the American Heart Association. Circulation. 2012; 125:e2-220. doi: 10.1161/CIR.0b013e31823ac046.
2. Braunwald E. Heart failure. JACC Heart Fail. 2013; 1:1-20. doi: 10.1016/j.jchf.2012.10.002.
3. Viswanathan G, Gilbert S. The Cardiorenal Syndrome: making the Connection. Int J Nephrol. 2010; 2011. 283137. doi: 10.4061/2011/283137.
4. Ismahil MA, Hamid T, Bansal SS, Patel B, Kingery JR, Prabhu SD. Remodeling of the mononuclear phagocyte network underlies chronic inflammation and disease progression in heart failure: critical importance of the cardiosplenic axis. Circ Res. 2014; 114:266-82. doi: 10.1161/CIRCRESAHA.113.301720.
5. Lopez EF, Kabarowski JH, Ingle KA, Kain V, Barnes S, Crossman DK, Lindsey ML, Halade GV. Obesity superimposed on aging magnifies inflammation and delays the resolving response after myocardial infarction. Am J Physiol Heart Circ Physiol. 2015; 308:H269-80. doi: 10.1152/ajpheart.00604.2014.
6. Swirski FK, Nahrendorf M. Leukocyte behavior in atherosclerosis, myocardial infarction, and heart failure. Science. 2013; 339:161-66. doi: 10.1126/science.1230719.
7. Libby P, Tabas I, Fredman G, Fisher EA. Inflammation and its resolution as determinants of acute coronary syndromes. Circ Res. 2014; 114:1867-79. doi: 10.1161/CIRCRESAHA.114.302699.
8. Kain V, Prabhu SD, Halade GV. Inflammation revisited: inflammation versus resolution of inflammation following myocardial infarction. Basic Res Cardiol. 2014; 109:444. doi: 10.1007/s00395-014-0444-7.
9. Serhan CN, Brain SD, Buckley CD, Gilroy DW, Haslett C, O'Neill LA, Perretti M, Rossi AG, Wallace JL. Resolution of inflammation: state of the art, definitions and terms. FASEB J. 2007; 21:325-32. doi: 10.1096/fj.06-7227rev.
10. Serhan CN. Pro-resolving lipid mediators are leads for resolution physiology. Nature. 2014; 510:92-101. doi: 10.1038/nature13479.
11. Halade GV, El Jamali A, Williams PJ, Fajardo RJ, Fernandes G. Obesity-mediated inflammatory microenvironment stimulates osteoclastogenesis and bone loss in mice. Exp Gerontol. 2011; 46:43-52. doi: 10.1016/j.exger.2010.09.014.
12. Sansbury BE, DeMartino AM, Xie Z, Brooks AC, Brainard RE, Watson LJ, DeFilippis AP, Cummins TD, Harbeson MA, Brittian KR, Prabhu SD, Bhatnagar A, Jones SP, Hill BG. Metabolomic analysis of pressureoverloaded and infarcted mouse hearts. Circ Heart Fail. 2014; 7:634-42. doi: 10.1161/CIRCHEARTFAILURE.114.001151.
13. Reina-Couto M, Carvalho J, Valente MJ, Vale L, Afonso J, Carvalho F, Bettencourt P, Sousa T, Albino-Teixeira A. Impaired resolution of inflammation in human chronic heart failure. Eur J Clin Invest. 2014; 44:527-38. doi: 10.1111/eci.12265.
14. Taegtmeyer H, Stanley WC. Too much or not enough of a good thing? Cardiac glucolipotoxicity versus lipoprotection. J Mol Cell Cardiol. 2011; 50:2-5. doi: 10.1016/j.yjmcc.2010.09.014.
15. Kayama Y, Minamino T, Toko H, Sakamoto M, Shimizu I, Takahashi H, Okada S, Tateno K, Moriya J, Yokoyama M, Nojima A, Yoshimura M, Egashira K, et al. Cardiac 12/15 lipoxygenase-induced inflammation is involved in heart failure. J Exp Med. 2009; 206:1565-74. doi: 10.1084/jem.20082596.
16. Halade GV, Rahman MM, Bhattacharya A, Barnes JL, Chandrasekar B, Fernandes G. Docosahexaenoic acidenriched fish oil attenuates kidney disease and prolongs median and maximal life span of autoimmune lupus-prone mice. J Immunol. 2010; 184:5280-86. doi: 10.4049/jimmunol.0903282.
17. Ramsden CE, Zamora D, Leelarthaepin B, Majchrzak-Hong SF, Faurot KR, Suchindran CM, Ringel A, Davis JM, Hibbeln JR. Use of dietary linoleic acid for secondary prevention of coronary heart disease and death: evaluation of recovered data from the Sydney Diet Heart Study and updated meta-analysis. BMJ. 2013; 346:e8707. doi: 10.1136/bmj.e8707.
18. Bock JS, Gottlieb SS. Cardiorenal syndrome: new perspectives. Circulation. 2010; 121:2592-600. doi: 10.1161/CIRCULATIONAHA.109.886473.
19. Salem NM, Lin YH, Moriguchi T, Lim SY, Salem N Jr, Hibbeln JR. Distribution of omega-6 and omega-3 polyunsaturated fatty acids in the whole rat body and 25 compartments. Prostaglandins Leukot Essent Fatty Acids. 2015; 100:13-20. doi: 10.1016/j.plefa.2015.06.002.
20. Kohli P, Levy BD. Resolvins and protectins: mediating solutions to inflammation. Br J Pharmacol. 2009; 158:960-71. doi: 10.1111/j.1476-5381.2009.00290.x.
21. Ricciotti E, FitzGerald GA. Prostaglandins and inflammation. Arterioscler Thromb Vasc Biol. 2011; 31:986-1000. doi: 10.1161/ATVBAHA.110.207449.
22. Mozaffarian D, Lemaitre RN, King IB, Song X, Spiegelman D, Sacks FM, Rimm EB, Siscovick DS. Circulating long-chain γ-3 fatty acids and incidence of congestive heart failure in older adults: the cardiovascular health study: a cohort study. Ann Intern Med. 2011; 155:160-70. doi: 10.7326/0003-4819-155-3-201108020-00006.
23. Ramsden CE, Hibbeln JR, Majchrzak SF, Davis JM. n-6 fatty acid-specific and mixed polyunsaturate dietary interventions have different effects on CHD risk: a meta-analysis of randomised controlled trials. Br J Nutr. 2010; 104:1586-600. doi: 10.1017/S0007114510004010.
24. Del Gobbo LC, Imamura F, Aslibekyan S, Marklund M, Virtanen JK, Wennberg M, Yakoob MY, Chiuve SE, Dela Cruz L, Frazier-Wood AC, Fretts AM, Guallar E, Matsumoto C, et al, and Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) Fatty Acids and Outcomes Research Consortium (FORCe). γ-3 Polyunsaturated Fatty Acid Biomarkers and Coronary Heart Disease: Pooling Project of 19 Cohort Studies. JAMA Intern Med. 2016; 176:1155-66. doi: 10.1001/jamainternmed.2016.2925.
25. Kirkby NS, Lundberg MH, Harrington LS, Leadbeater PD, Milne GL, Potter CM, Al-Yamani M, Adeyemi O, Warner TD, Mitchell JA. Cyclooxygenase-1, not cyclooxygenase-2, is responsible for physiological production of prostacyclin in the cardiovascular system. Proc Natl Acad Sci USA. 2012; 109:17597-602. doi: 10.1073/pnas.1209192109.
26. Cannon CP, Cannon PJ. Physiology. COX-2 inhibitors and cardiovascular risk. Science. 2012; 336:1386-87. doi: 10.1126/science.1224398.
27. Oni-Orisan A, Edin ML, Lee JA, Wells MA, Christensen ES, Vendrov KC, Lih FB, Tomer KB, Bai X, Taylor JM, Stouffer GA, Zeldin DC, Lee CR. Cytochrome P450-derived epoxyeicosatrienoic acids and coronary artery disease in humans: a targeted metabolomics study. J Lipid Res. 2016; 57:109-19. doi: 10.1194/jlr.M061697.
28. Dhingra S, Li P, Huang XP, Guo J, Wu J, Mihic A, Li SH, Zang WF, Shen D, Weisel RD, Singal PK, Li RK. Preserving prostaglandin E2 level prevents rejection of implanted allogeneic mesenchymal stem cells and restores postinfarction ventricular function. Circulation. 2013 (Suppl 1); 128:S69-78. doi: 10.1161/CIRCULATIONAHA.112.000324.
29. Hsueh YC, Wu JM, Yu CK, Wu KK, Hsieh PC. Prostaglandin E2 promotes post-infarction cardiomyocyte replenishment by endogenous stem cells. EMBO Mol Med. 2014; 6:496-503.
30. Swirski FK, Nahrendorf M, Etzrodt M, Wildgruber M, Cortez-Retamozo V, Panizzi P, Figueiredo JL, Kohler RH, Chudnovskiy A, Waterman P, Aikawa E, Mempel TR, Libby P, et al. Identification of splenic reservoir monocytes and their deployment to inflammatory sites. Science. 2009; 325:612-16. doi: 10.1126/science.1175202.
31. Emami H, Singh P, MacNabb M, Vucic E, Lavender Z, Rudd JH, Fayad ZA, Lehrer-Graiwer J, Korsgren M, Figueroa AL, Fredrickson J, Rubin B, Hoffmann U, et al. Splenic metabolic activity predicts risk of future cardiovascular events: demonstration of a cardiosplenic axis in humans. JACC Cardiovasc Imaging. 2015; 8:121-30. doi: 10.1016/j.jcmg.2014.10.009.
32. Leuschner F, Rauch PJ, Ueno T, Gorbatov R, Marinelli B, Lee WW, Dutta P, Wei Y, Robbins C, Iwamoto Y, Sena B, Chudnovskiy A, Panizzi P, et al. Rapid monocyte kinetics in acute myocardial infarction are sustained by extramedullary monocytopoiesis. J Exp Med. 2012; 209:123-37. doi: 10.1084/jem.20111009.
33. Halade GV, Rahman MM, Williams PJ, Fernandes G. High fat diet-induced animal model of age-associated obesity and osteoporosis. J Nutr Biochem. 2010; 21:1162-69. doi: 10.1016/j.jnutbio.2009.10.002.
34. Epelman S, Lavine KJ, Randolph GJ. Origin and functions of tissue macrophages. Immunity. 2014; 41:21-35. doi: 10.1016/j.immuni.2014.06.013.
35. Molawi K, Wolf Y, Kandalla PK, Favret J, Hagemeyer N, Frenzel K, Pinto AR, Klapproth K, Henri S, Malissen B, Rodewald HR, Rosenthal NA, Bajenoff M, et al. Progressive replacement of embryo-derived cardiac macrophages with age. J Exp Med. 2014; 211:2151-58. doi: 10.1084/jem.20140639.
36. Ponnappan S, Ponnappan U. Aging and immune function: molecular mechanisms to interventions. Antioxid Redox Signal. 2011; 14:1551-85. doi: 10.1089/ars.2010.3228.
37. Shaw AC, Goldstein DR, Montgomery RR. Agedependent dysregulation of innate immunity. Nat Rev Immunol. 2013; 13:875-87. doi: 10.1038/nri3547.
38. Bruunsgaard H, Andersen-Ranberg K, Hjelmborg J, Pedersen BK, Jeune B. Elevated levels of tumor necrosis factor alpha and mortality in centenarians. Am J Med. 2003; 115:278-83. doi: 10.1016/S0002-9343(03)00329-2.
39. Ershler WB, Keller ET. Age-associated increased interleukin-6 gene expression, late-life diseases, and frailty. Annu Rev Med. 2000; 51:245-70. doi: 10.1146/annurev.med.51.1.245.
40. Franceschi C, Bonafè M, Valensin S, Olivieri F, De Luca M, Ottaviani E, De Benedictis G. Inflamm-aging. An evolutionary perspective on immunosenescence. Ann N Y Acad Sci. 2000; 908:244-54. doi: 10.1111/j.1749-6632.2000.tb06651.x.
41. Baylis D, Bartlett DB, Patel HP, Roberts HC. Understanding how we age: insights into inflammaging. Longev Healthspan. 2013; 2:8. doi: 10.1186/2046-2395-2-8.
42. ter Maaten JM, Valente MA, Damman K, Hillege HL, Navis G, Voors AA. Diuretic response in acute heart failure-pathophysiology, evaluation, and therapy. Nat Rev Cardiol. 2015; 12:184-92. doi: 10.1038/nrcardio.2014.215.
43. Colombo PC, Ganda A, Lin J, Onat D, Harxhi A, Iyasere JE, Uriel N, Cotter G. Inflammatory activation: cardiac, renal, and cardio-renal interactions in patients with the cardiorenal syndrome. Heart Fail Rev. 2012; 17:177-90. doi: 10.1007/s10741-011-9261-3.
44. Iacoviello M, Leone M, Antoncecchi V, Ciccone MM. Evaluation of chronic kidney disease in chronic heart failure: from biomarkers to arterial renal resistances. World J Clin Cases. 2015; 3:10-19. doi: 10.12998/wjcc.v3.i1.10.
45. Devarajan P. Neutrophil gelatinase-associated lipocalin: a promising biomarker for human acute kidney injury. Biomarkers Med. 2010; 4:265-80. doi: 10.2217/bmm.10.12.
46. Smith SC Jr, Allen J, Blair SN, Bonow RO, Brass LM, Fonarow GC, Grundy SM, Hiratzka L, Jones D, Krumholz HM, Mosca L, Pasternak RC, Pearson T, et al, and AHA/ACC, and National Heart, Lung, and Blood Institute. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute. Circulation. 2006; 113:2363-72. doi: 10.1161/CIRCULATIONAHA.106.174516.
47. Mozaffarian D, Rimm EB. Fish intake, contaminants, and human health: evaluating the risks and the benefits. JAMA. 2006; 296:1885-99. doi: 10.1001/jama.296.15.1885.
48. Eckel RH. The fish oil story remains fishy. Circulation. 2010; 122:2110-12. doi: 10.1161/CIRCULATIONAHA.110.986976.
49. Ma Y, Halade GV, Zhang J, Ramirez TA, Levin D, Voorhees A, Jin YF, Han HC, Manicone AM, Lindsey ML. Matrix metalloproteinase-28 deletion exacerbates cardiac dysfunction and rupture after myocardial infarction in mice by inhibiting M2 macrophage activation. Circ Res. 2013; 112:675-88. doi: 10.1161/CIRCRESAHA.111.300502.
50. Kain V, Ingle KA, Colas RA, Dalli J, Prabhu SD, Serhan CN, Joshi M, Halade GV. Resolvin D1 activates the inflammation resolving response at splenic and ventricular site following myocardial infarction leading to improved ventricular function. J Mol Cell Cardiol. 2015; 84:24-35. doi: 10.1016/j.yjmcc.2015.04.003.